These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 7736525)
1. Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein. Dougall WC; Greene MI Cell Biophys; 1994; 24-25():209-18. PubMed ID: 7736525 [TBL] [Abstract][Full Text] [Related]
2. Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation. Qian X; O'Rourke DM; Drebin J; Zhao H; Wang Q; Greene MI DNA Cell Biol; 1997 Dec; 16(12):1395-405. PubMed ID: 9428788 [TBL] [Abstract][Full Text] [Related]
3. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy. Stancovski I; Peles E; Ben Levy R; Lemprecht R; Kelman Z; Goldman-Michael R; Hurwitz E; Bacus S; Sela M; Yarden Y J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):95-103. PubMed ID: 1356018 [TBL] [Abstract][Full Text] [Related]
4. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Cohen JA; Weiner DB; More KF; Kokai Y; Williams WV; Maguire HC; LiVolsi VA; Greene MI Oncogene; 1989 Jan; 4(1):81-8. PubMed ID: 2563577 [TBL] [Abstract][Full Text] [Related]
5. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Yu D; Wang SS; Dulski KM; Tsai CM; Nicolson GL; Hung MC Cancer Res; 1994 Jun; 54(12):3260-6. PubMed ID: 7911396 [TBL] [Abstract][Full Text] [Related]
6. Immunological prevention of spontaneous tumors: a new prospect? Quaglino E; Rovero S; Cavallo F; Musiani P; Amici A; Nicoletti G; Nanni P; Forni G Immunol Lett; 2002 Feb; 80(2):75-9. PubMed ID: 11750037 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Drebin JA; Link VC; Greene MI Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329 [TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702 [TBL] [Abstract][Full Text] [Related]
9. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Weiner LM; Clark JI; Ring DB; Alpaugh RK J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384 [TBL] [Abstract][Full Text] [Related]
10. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Hong RL; Spohn WH; Hung MC Clin Cancer Res; 1999 Jul; 5(7):1884-91. PubMed ID: 10430096 [TBL] [Abstract][Full Text] [Related]
11. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965 [TBL] [Abstract][Full Text] [Related]
12. New insights into anti-HER-2 receptor monoclonal antibody research. Kumar R; Mandal M; Vadlamudi R Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Zhang H; Richter M; Greene MI Cancer Biol Ther; 2003; 2(4 Suppl 1):S122-6. PubMed ID: 14508089 [TBL] [Abstract][Full Text] [Related]
14. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation. Meenakshi A; Kumar RS; Kumar NS Hum Antibodies; 2001; 10(3-4):101-7. PubMed ID: 11847421 [TBL] [Abstract][Full Text] [Related]
15. p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2. Wildenhain Y; Pawson T; Blackstein ME; Andrulis IL Oncogene; 1990 Jun; 5(6):879-83. PubMed ID: 1694290 [TBL] [Abstract][Full Text] [Related]
16. Biological effects of monoclonal antireceptor antibodies reactive with neu oncogene product, p185neu. Myers JN; Drebin JA; Wada T; Greene MI Methods Enzymol; 1991; 198():277-90. PubMed ID: 1677444 [No Abstract] [Full Text] [Related]
17. The effects of the normal and oncogenic forms of the neu tyrosine kinase, and the corresponding forms of an immunoglobulin E receptor/neu tyrosine kinase fusion protein, on Xenopus oocyte maturation. Narasimhan V; Hamill O; Cerione RA FEBS Lett; 1992 Jun; 303(2-3):164-8. PubMed ID: 1351469 [TBL] [Abstract][Full Text] [Related]
18. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Lai GH; Zhang Z; Shen XN; Ward DJ; Dewitt JL; Holt SE; Rozich RA; Hixson DC; Sirica AE Gastroenterology; 2005 Dec; 129(6):2047-57. PubMed ID: 16344070 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Di Carlo E; Rovero S; Boggio K; Quaglino E; Amici A; Smorlesi A; Forni G; Musiani P Clin Cancer Res; 2001 Mar; 7(3 Suppl):830s-837s. PubMed ID: 11300480 [TBL] [Abstract][Full Text] [Related]
20. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Hurwitz E; Stancovski I; Sela M; Yarden Y Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3353-7. PubMed ID: 7724565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]